Healthy Extracts (HYEX) Common Equity (2015 - 2025)
Healthy Extracts' (HYEX) quarterly Common Equity came in at $24.0 million in Q4 2025, up 5755.49% year-on-year from $410377.0 in Q4 2024, and little changed quarter-over-quarter from $24.1 million in Q3 2025.
Healthy Extracts (HYEX) Common Equity (2015 - 2025) Analysis & Trends
Healthy Extracts' Common Equity history runs 11 years deep, the most recent figure standing at $24.0 million for Q4 2025.
- On a quarterly basis, Common Equity rose 5755.49% year-over-year to $24.0 million in Q4 2025; TTM through Dec 2025 was $24.0 million, a 5755.49% increase from a year earlier, with the FY2025 full-year figure at $24.0 million, up 5755.49% from the prior year.
- Common Equity was little changed at $24.0 million in Q4 2025 per HYEX's latest filing, from $24.1 million in the prior quarter.
- Across five years, Common Equity topped out at $24.1 million in Q3 2025 and bottomed at $60508.0 in Q1 2025.
- The 5-year median for Common Equity is $1.2 million (2023), against an average of $3.5 million.
- Across the five-year window, Common Equity slumped 88.47% in 2024 and jumped 5755.49% in 2025, its largest moves.
- Year by year, Common Equity stood at $2.5 million in 2021, then declined by 24.25% to $1.9 million in 2022, then slumped by 48.99% to $954590.0 in 2023, then tumbled by 57.01% to $410377.0 in 2024, then soared by 5755.49% to $24.0 million in 2025.
- Per Business Quant, the three latest HYEX Common Equity figures stand at $24.0 million (Q4 2025), $24.1 million (Q3 2025), and $477958.0 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 21.93 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.23 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 3.23 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 47.38 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 5.90 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 56.13 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 14.66 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 3.41 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.50 Bn |
| 10 | Healthy Extracts | 14.70 Mn | 14.56 Mn | 957,429.00 | 24.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 24.03 Mn |
| Sep 30, 2025 | 24.06 Mn |
| Jun 30, 2025 | 477,958.00 |
| Mar 31, 2025 | 60,508.00 |
| Dec 31, 2024 | 410,377.00 |
| Sep 30, 2024 | 802,961.00 |
| Jun 30, 2024 | 400,000.00 |
| Mar 31, 2024 | 151,646.00 |
| Dec 31, 2023 | 954,590.00 |
| Sep 30, 2023 | 1.02 Mn |
| Jun 30, 2023 | 1.18 Mn |
| Mar 31, 2023 | 1.32 Mn |
| Dec 31, 2022 | 1.87 Mn |
| Sep 30, 2022 | 1.83 Mn |
| Jun 30, 2022 | 1.97 Mn |
| Mar 31, 2022 | 2.45 Mn |
| Dec 31, 2021 | 2.47 Mn |
| Sep 30, 2021 | 989,804.00 |
| Jun 30, 2021 | 1.57 Mn |
| Mar 31, 2021 | 2.07 Mn |